I-Mab Biopharma
IMAB
#9465
Rank
NZ$99.43 M
Marketcap
$1.22
Share price
-6.87%
Change (1 day)
-59.46%
Change (1 year)

Revenue for I-Mab Biopharma (IMAB)

Revenue in 2024 (TTM): NZ$5.7 Million

According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is NZ$6.43 Million. In 2023 the company made a revenue of NZ$0.98 Million an increase over the revenue in the year 2022 that were of -NZ$8.36 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for I-Mab Biopharma from 2017 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$5.7 M475.93%
2023 NZ$0.98 M-111.85%
2022-NZ$8.36 Million-314.85%
2021NZ$3.88 M-94.01%
2020 NZ$64.95 M5798.4%
2019 NZ$1.1 M-46.01%
2018 NZ$2.03 M317.83%
2017NZ$0.48 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
NZ$0.4 M-93.70%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.27 B 19,776.95%๐Ÿ‡บ๐Ÿ‡ธ USA